Head and neck cancer (HNC) is the seventh most common cancer type in the world and said to result in around 360,000 deaths each year. The National Institutes of Health has reported that up to 80% of ...

Esophageal squamous cell carcinoma accounts for approximately 90% of all esophageal cancer cases. Projections estimate that ...

The US Food and Drug Administration has approved tislelizumab (Tevimbra, BeiGene), in combination with platinum-containing ...

The FDA has approved Tevimbra (tislelizumab) for use in combination with chemotherapy as first-line treatment for unresectable or metastatic, PD-L1-positive ESCC.

Tislelizumab plus chemotherapy received FDA approval as a frontline therapy for individuals with unresectable or metastatic ...

The approval for the first-line treatment of esophageal squamous cell carcinoma comes shortly after a label expansion for the ...

Tislelizumab plus chemotherapy is now FDA-approved for metastatic esophageal squamous cell carcinoma with a tumor PD-L1 ...

The FDA approved Tevimbra with chemotherapy for adults with unresectable or metastatic esophageal squamous cell carcinoma ...

BeiGene's Tevimbra wins FDA approval for first-line metastatic ESCC treatment, showing significant survival benefits in PD-L1 ...

BeiGene (ONC) has received FDA approval for Tevimbra for first-line esophageal cancer with chemo. Read more here.

It took nearly three years to win presumptive workers' compensation coverage for breast, cervical, and other cancers that ...

Greater adherence to the Mediterranean diet is associated with a modest reduction in obesity-related cancer risk ...